TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07783425: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PART

Sponsor: Pfizer · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 1375 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,034,112

Rescue Site Savings

+$4,652,772

Unlock Full NCT07783425 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07783425 Rescue Dossier →